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Therapeutic concentrations of cyclosporine A, but not FK506,
increase P-glycoprotein expression in endothelial and renal tu-
bule cells.
Background. The immunosuppressive drugs cyclosporine A
(CsA) and tacrolimus (FK506) are extruded from cells by the
multidrug resistance P-glycoprotein (P-gp), an efflux pump for
drugs and xenobiotics, which may limit their therapeutic effective-
ness and/or incidence of toxic side effects. In the present study, we
investigated the effect of therapeutic concentrations of CsA and
FK506 on the expression of P-gp in cultured endothelial and
proximal tubule cells.
Methods. P-gp expression in human arterial endothelial
(HAEC) and rat proximal tubule cells (RPTC) was determined by
immunoblotting and immunocytochemistry, and correlated with
P-gp-mediated transport by measuring the intracellular accumu-
lation of the fluorescent probe calcein.
Results. Following incubation of HAEC with therapeutic con-
centrations of 0.1 to 1.6 mM CsA up to seven days, P-gp expression
increased in a time- and concentration-dependent manner, max-
imally to 291 6 42% of controls with 0.8 mM CsA for seven days.
Similar effects of CsA were observed in RPTC. In contrast,
therapeutic concentrations of FK506 (0.01 to 0.2 mM up to 7 days)
did not change P-gp expression in either cell type, though at
higher, supratherapeutic concentrations of FK506 (0.6 to 1.2 mM)
P-gp expression was also increased. Immunocytochemistry re-
vealed increased P-gp expression in the plasma membrane of
HAEC and RPTC treated with 0.8 mM CsA, which was reflected
by a decrease of P-gp-mediated accumulation of calcein in both
cell types.
Conclusions. The data suggest that the induction of P-gp
expression in HAEC and RPTC at concentrations of CsA or
FK506 above 0.5 mM is part of the protective answer of cells to
toxic concentrations of the drugs and could therefore interfere
with the therapeutic effectiveness of CsA in vivo.
Multidrug resistance P-glycoprotein (P-gp) is a 170 kD
transmembrane protein, which is encoded by a small gene
family comprising two members in humans (MDR1 and
MDR2) and three members in rodents (mdr1, mdr2 and
mdr3) [1]. Only the P-gp MDR1 in humans and mdr1 and
mdr3 in rodents convey drug resistance [2]. MDR1 is
abundant in many drug resistant human tumors, but is also
present in various epithelial tissues, such as liver, intestine,
kidney and endothelia of the blood-brain barrier [3, 4]. In
these cells, MDR1 is expressed in the luminal plasma
membrane where it acts as ATP-dependent efflux pump for
various hydrophobic, potentially toxic endogenous and
xenobiotic compounds [5, 6], including chemotherapeutics
and immunosuppressive drugs [7].
The cyclic undecapeptide cyclosporine A (CsA) and the
cyclic macrolide tacrolimus (FK506) are two potent immu-
nosuppressants used for renal transplant recipients.
Whereas both drugs have the same immunosuppressive
mode of action, namely binding to immunophilins and
inhibition of calcineurin-calmodulin-induced dephosphory-
lation of the NF-AT factor required for transcription of
“early” T-cell activation genes (IL-2, c-myc, IL-3, TNFa,
IFN-g) by calcineurin-phosphatase [8], on a molar basis
FK506 is 10- to 100-fold more potent than CsA [9–11]. This
explains why FK506 is effective at lower concentrations
than CsA in transplant recipients [12] and can also be used
for anti-rejection therapy [13]. Acute and chronic nephro-
toxicity are major adverse effects of both drugs; they occur
with a similar frequency [14, 15] and involve tubular and
endothelial damage resulting in some degree of renal
dysfunction [16–18].
CsA and FK506 are also actively transported by P-gp [7].
The affinity of CsA and FK506 for P-gp transport is
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unrelated to the immunosuppressive effect. This transport
may decrease their therapeutic effectiveness, but also the
incidence of toxic side effects in target cells. Since exposure
of cells to supratherapeutic concentrations of CsA in-
creases the expression of P-gp in vitro [19] and in vivo [20],
it seemed pertinent to investigate whether therapeutic
concentrations of CsA or FK506 increase the expression
level of P-gp. To that end, therapeutic and supratherapeu-
tic concentrations of CsA or FK506 were tested on endo-
thelial and kidney proximal tubule cell lines expressing
substantial basal levels of P-gp.
METHODS
Materials
The following reagents were obtained from the listed
sources and used at the concentrations indicated in the text.
Stock solutions of calcein-AM ester (Molecular Probes,
Eugene, OR, USA), cyclosporine A (Sigma, Deisenhofen,
Germany or kindly provided by Novartis, Basel, Switzer-
land) and FK506 (kindly provided by Fujisawa, Munich,
Germany) were made by solubilization in dimethyl sulphox-
ide (DMSO). Verapamil (Aldrich Chemie, Steinheim, Ger-
many) was dissolved in ethanol. Rat tail collagen type I
(Sigma) was dissolved in 100 mM acetic acid. C219 mono-
clonal antibody (mAb; Alexis Deutschland, Gru¨nberg, Ger-
many) and MRK-16 mAb (Biozol, Eching, Germany) were
used for the detection of P-gp. The monoclonal antibody to
the a-subunit of the Na1/K1-ATPase (monoclonal anti-
body a5-IgG) [21] was a kind gift of Dr. J.-P. Hildebrandt
(II. Physiologisches Institut, Universita¨t des Saarlandes,
Homburg/Saar, Germany). A monoclonal horseradish per-
oxidase (HRP)-conjugated rabbit anti-mouse antibody,
peroxidase (POD)-conjugated goat anti-rabbit antibody
and the chromogenic substrate 3-amino-9-ethylcarbazole
(AEC) were from DAKO Diagnostika (Hamburg, Germa-
ny). HRP-conjugated sheep-anti-mouse IgG and enhanced
chemiluminescence reagents were purchased from Amer-
sham-Buchler (Braunschweig, Germany). Non-fat dry milk
and prestained protein standards were from Bio-Rad (Mu-
nich, Germany). Polyvinylidene difluoride (PVDF) mem-
branes were from NEN-Dupont (Bad Homburg, Germa-
ny). All other substances were from commercial sources
and of analytical grade.
Cell culture
Human arterial endothelial cells (HAEC) from the iliac
artery of an organ donor were obtained from the Coriell
Institute for Medical Research (Camden, NJ, USA). The
endothelial cell nature of the cultures was confirmed by
immunofluorescence staining for the presence of von Wil-
lebrand factor and the homogenous expression of
PECAM-1 (CD31) [22]. HAEC were cultured in medium
M199, enriched with 20% fetal calf serum (FCS), bovine
hypothalamic growth factor (ECGF), and heparin. The
cells were plated on gelatin-coated flasks, split 1:2 once a
week and used for experiments between passages 8 and 20.
Immortalized cells (WKPT-1292 Cl.8) of the S1 segment
of the proximal tubule of normotensive Wistar-Kyoto rats
(RPTC) were cultured as described earlier [23]. Briefly,
cells were maintained in renal tubular epithelium medium
composed of Dulbecco’s modified Eagle’s Medium
(DMEM):F-12 [nutrient mixture F-12 (Ham)] 1:1 and
supplemented with 15 mM HEPES, 1.2 mg/ml NaHCO3, 5
mg/ml insulin, 5 mg/ml transferrin, 10 ng/ml epidermal
growth factor, 4 mg/ml dexamethasone, 100 U/ml penicillin
G, 100 mg/ml streptomycin sulfate and 5% fetal calf serum.
Cells were plated on rat tail collagen type I (125 mg/ml 100
mM acetic acid)-coated flasks, passaged at 80% confluency
and split 1:10 twice a week.
To validate comparisons of different drugs and experi-
ments, only cultures at confluency were employed that
allowed the same cell to drug ratio.
Immunocytochemistry of P-gp in single cells (cytospin)
Cells were incubated in the presence or absence of CsA
(0.8 mM) or FK506 (0.1 mM) for seven days, trypsinized and
resuspended in culture medium plus 20% FCS. After
cytospinning onto glass slides, cells were briefly fixed in 4%
paraformaldehyde, rinsed in phosphate buffered saline
(PBS) and stained according to the following protocol:
Endogenous peroxidase activity was quenched for 15 min-
utes with 0.3% H2O2 in methanol (vol/vol) at room tem-
perature (RT). To reduce unspecific binding, slides were
incubated for 30 minutes with pooled heat-inactivated
human serum diluted 1:5 in PBS. Slides were incubated for
60 minutes with mAb MRK-16 (1:100) or mouse IgG as a
negative control. The first secondary antibody, a HRP-
conjugated rabbit anti-mouse antibody, was applied for 30
minutes at RT at a dilution of 1:50. To amplify the
immunoperoxidase reaction, another secondary antibody, a
goat anti-rabbit POD-conjugated antibody, was also ap-
plied at a dilution of 1:100 for 30 minutes at RT. After
washing, the slides were incubated with the chromogenic
substrate 3-amino-9-ethylcarbazole for three minutes at RT
and counterstained with hematoxylin. This resulted in a red
reaction product in positively labeled cells. Slides were
washed once more, mounted in glycerol-gelatine and
viewed with a non-inverted microscope using objectives of
103, 203 and 403. Images were taken with a Zeiss camera
using an Agfachrome RSX50 film.
SDS-PAGE and Western blotting
After washing three times with PBS, HAEC or RPTC
were scraped off the culture flasks with a rubber policeman,
centrifuged and the cell pellet was resuspended in 80 ml of
a buffer containing (in mM) mannitol 280, HEPES 10,
EDTA 5, MgSO4 0.1, Pefabloc
® 0.2 and 10 mg/ml leupeptin
(pH 7.0 adjusted with Tris). Cells were solubilized by
addition of 40 ml of three-times concentrated SDS sample
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buffer and sonicated for 30 seconds on ice. Following
centrifugation at 12,000 3 g for five minutes, the protein
content of the supernatant was determined by the method
of Lowry et al [24]. Following incubation of samples at 37°C
for 30 minutes, 50 mg of membrane protein was loaded
onto each lane of the gel. Electrophoresis and blotting
procedures were performed essentially as described earlier
[25]. Proteins were separated by SDS-PAGE on 7.5%
acrylamide Laemmli [26] minigels and transferred onto
PVDF membranes overnight. The efficiency of protein
transfer was monitored with prestained protein standards.
Blots were blocked with 3% nonfat dry milk in Tris-
buffered saline containing 0.05% Tween 20 for six hours
and incubated with primary antibodies against P-gp (5
mg/ml C219) or Na1/K1-ATPase (0.5 mg/ml Aba5) over-
night. Following incubation with HRP-conjugated second-
ary antibody (1:6,000 dilution) for 60 minutes, blots were
developed in enhanced chemiluminescence reagents and
signals were visualized on X-ray films. X-ray films were
scanned with a single pass flat-bed scanner (Linotype-Hell,
Eschborn, Germany) and processed for documentation
using a JASC Paint Shop Pro 4.1 software (Jameln, Ger-
many). The intensity of the Western blot signals was further
enhanced with a Corel Photo-Paint 5.0 software (Corel
Corporation Limited, Ru¨sselsheim, Germany). Signals
from different experiments were scanned, and the intensity
(optical density) of the chemiluminescence signals was
quantified on a Bioprofil computer assisted imaging and
scanning system (Vilber-Lourmat, Marne La Valle´e,
France).
Calcein-AM assay for P-gp activity
Twelve hours before each experiment, the medium of
cells incubated for seven days with DMSO or the immuno-
suppressive drugs CsA (0.8 mM) or FK506 (0.1 mM) was
replaced by medium without drugs or solvent. Cells were
then trypsinized, washed and stored in DMEM at 25°C.
Calcein accumulation was measured in constantly stirred
cell suspensions (5 3 105 cells/ml) in 3 ml of Tyrode
solution containing (in mM) NaCl 140, KCl 5, CaCl2 1,
MgCl2 1, HEPES 10, adjusted to pH 7.4 with NaOH, as
described previously [27]. Calcein-AM is a nonfluorescent,
highly lipid soluble dye that rapidly penetrates the plasma
membrane of cells. Once inside the cell, ester bonds are
cleaved by endogenous esterases, transforming calcein-AM
into hydrophilic and intensely fluorescent calcein. Cells
expressing high levels of P-gp rapidly extrude non-fluores-
cent calcein-AM from the plasma membrane, thereby
reducing accumulation of fluorescent calcein in the cytosol.
The amount of P-gp activity is therefore inversely propor-
tional to the accumulation of intracellular calcein fluores-
cence. Calcein-AM (Molecular Probes, Eugene, OR, USA)
was used at 0.25 mM. Fluorescence was measured with a
FluoroMax-2 (Jobin Yvon-Spex; Instruments S.A., Edison,
NJ, USA) fluorimeter (37°C, lex 493 nm; lem 515 nm; band
width 5 nm).
Statistics
All experiments were repeated at least three times with
different batches of cell preparations and representative
data or means 6 SD are shown. Statistical analysis was
carried out with the Statgraphics program using the un-
paired Student’s t-test. Results with levels of P , 0.05 were
considered significant.
RESULTS
Human arterial endothelial cells
In immunohistochemical studies of specimens from renal
tissue and human vessels we observed a preferential expres-
sion of P-gp in arterial as compared to venous endothelia.
We also confirmed the differential expression of P-gp in
arterial and venous vascular endothelia in a cell culture
system with human endothelial cells from the iliac artery
and vein from an organ donor (I.A. Hauser, M. Koziolek,
F. The´venod, manuscript in preparation). Since immuno-
suppressive drug-induced nephropathy is also associated
with degenerative changes in the walls of renal arterioles
[16–18], we investigated the effect of the immunosuppres-
sants CsA and FK506 on the expression and function of
P-gp in cultured human arterial endothelial cells (HAEC).
The presence of P-gp was ascertained by Western blot
analysis with the P-gp specific mAb C219 (5 mg/ml) [28].
C219 mAb is directed against two intracellular domains of
P-gp close to its ATP-binding site [29]. Figure 1A shows a
representative immunoblot of lysates from HAEC that had
been incubated with therapeutically relevant concentra-
tions of CsA (0.1 to 1.6 mM) or FK506 (0.01 to 0.2 mM) for
seven days. The first lane of each blot (Fig. 1A) shows
constitutive expression of P-gp in HAEC. Concentrations
of FK506 chosen were 8 to 10 times lower than those of
CsA, as FK506 is at least 10 times more potent in terms of
immunosuppression [12]. Figure 1B summarizes a quanti-
tative analysis of immunoblots from five different experi-
ments. P-gp expression was quantified by measuring the
optical density of immunoreactive bands with controls set
to 100%. The C219 mAb labeled a band of ;170 kD, as
expected for full size P-gp. CsA treatment for seven days
increased P-gp expression, starting with a concentration of
0.2 mM (Fig. 1 A, B). P-gp expression was increased
maximally to 291 6 42% of controls by 0.8 mM CsA (P ,
0.05; Fig. 1B). FK506 treatment essentially did not change
P-gp expression at the therapeutically relevant concentra-
tions of 0.01 to 0.2 mM tested for seven days (Fig. 1 A, B).
However, at higher concentrations FK506 also increased
P-gp expression to similar levels as CsA (284 6 34% at 1.2
mM FK506, N 5 5; P , 0.05; Fig. 1B). In contrast, no
changes in the expression of the a-subunit of the Na1/K1-
ATPase, as determined with the monoclonal antibody
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Fig. 1. Expression of P-gp and Na1/K1-ATPase in lysates from human arterial endothelial cells (HAEC) treated for seven days with different concentrations
of cyclosporine A (CsA) or FK506. (A) The immunoblot was probed with mAb C219 (5 mg/ml). HAEC were pretreated for seven days with either 0.1% (vol/vol)
DMSO in controls (lane 1) and 0.1 to 1.6 mM CsA (upper immunoblot) or 0.01–0.2 mM FK506 (lower immunoblot). (B) Quantification of P-gp expression in
HAEC treated with 0.1 to 1.6 mM CsA for seven days (left) or HAEC treated with 0.01 to 1.2 mM FK506 for seven days (right). Immunoreactive bands were
analyzed by densitometry, and P-gp expression was expressed as a percentage of the total amount of immunoreactive protein present in HAEC that had been
treated with 0.1% (vol/vol) DMSO for seven days. Values represent means 6 SD of 5 different experiments. *P , 0.05 using unpaired Student’s t-test. (C) The
immunoblot was probed with mAb Aba5 (0.5 mg/ml). HAEC were pretreated for seven days with either 0.1% (vol/vol) DMSO in controls, 0.8 and 1.6 mM CsA,
or 0.6 and 1.2 mM FK506. The blot is typical for three different preparations.
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Aba5 (0.5 mg/ml), was detected following a seven-day
treatment of HAEC with 0.8 to 1.6 mM CsA or 0.6 to 1.2 mM
FK506 (Fig. 1C).
Next, we investigated the time-dependence of the effect
of CsA on the expression of P-gp in HAEC, which had been
treated with 0.8 mM CsA for one to seven days. After 24
hours of incubation with 0.8 mM CsA P-gp expression was
slightly, but not significantly, increased compared to control
conditions (172 6 52%, N 5 3; NS). After two days, P-gp
expression was significantly increased (246 6 32%, N 5 3;
P , 0.05) and remained significantly elevated at five days
(292 6 45%, N 5 3; P , 0.05) and seven days of CsA
incubation (312 6 37%, N 5 3; P , 0.05) compared to
control conditions (Fig. 2).
Whereas Western blot analyses of HAEC showed that
CsA exposure for seven days increased P-gp expression by
about two- to threefold in these cells, the functionally
relevant localization of P-gp in the plasma membrane of
HAEC remained to be determined. The mAb MRK-16
binds to an external domain of P-gp [30] and is therefore
suitable for detection of P-gp expressed in the plasma
membrane of intact cells. Immunocytochemical detection
of P-gp (cytospin) was carried out with the mAb MRK-16
(dilution 1:100) in controls and HAEC that had been
treated for seven days with 0.8 mM CsA or 0.1 mM FK506.
MRK-16 immunoreactivity on the cell surface of control
HAEC turned out to be weak, as shown in Figure 3A. In
cells treated with 0.8 mM CsA for seven days, immunostain-
ing on the cell surface was enhanced (Fig. 3B). In contrast,
MRK-16 immunostaining in HAEC treated with 0.1 mM
FK506 for seven days did not differ from controls (Fig. 3C).
The function of P-gp in the plasma membrane of HAEC
was assessed by measuring the time course of intracellular
accumulation of fluorescent calcein in the absence or
presence of known inhibitors of P-gp. This assay utilizes the
fluorogenic dye calcein acetoxymethyl ester (calcein-AM)
as a substrate for efflux activity of P-gp [27]. In control
HAEC, the addition of 0.25 mM calcein-AM resulted in a
high and constant rate of calcein accumulation in the cells
following an initial lag time of ;100 seconds (Fig. 4).
Addition of the P-gp inhibitor verapamil [31] did not
further increase the slope of the fluorescence curve (Fig. 4,
control curve). To account for possible differences between
control and drug-treated cells, for example, in the activity
of intracellular esterases, a dye accumulation ratio was
calculated by dividing the rate of net calcein uptake in the
presence of the inhibitor by the rate of uptake in the
absence of inhibitor [32]. Slopes (rates) were calculated
from linear regression. Table 1 shows the accumulation
ratios (means 6 SD) obtained with the solvent DMSO or
with two inhibitors of P-gp, verapamil and CsA [31, 33].
The accumulation ratios of calcein uptake in the presence
of DMSO or of the inhibitors of P-gp were not different in
control HAEC, suggesting that no or very low levels of
functional P-gp were expressed in the plasma membrane of
these cells (see also Fig. 3A). In HAEC, which had been
pretreated with 0.8 mM CsA for seven days, the accumula-
tion rate of calcein was decreased (Fig. 4, CsA curve). This
is expected for cells that overexpress P-gp in their plasma
membranes (Fig. 3B) because P-gp extrudes non-fluores-
cent calcein-AM from the cell, thereby reducing accumu-
lation of fluorescent calcein in the cytosol. Addition of 100
mM verapamil to the cuvette increased the slope of the
fluorescence time course (Fig. 4). A total of 100 mM
verapamil or 5 mM CsA, which also inhibits P-gp at these
supratherapeutic concentrations [33], accelerated the net
accumulation of calcein 3.2- to 4-fold (Table 1). In contrast,
in HAEC that had been pretreated with 0.1 mM FK506 for
seven days, calcein uptake in the absence and presence of
inhibitors of P-gp was not different from controls (Fig. 4
and Table 1). This observation is in agreement with the low
levels of P-gp detected in FK506-treated HAEC (Figs. 1
and 3C).
Rat proximal tubule cells
Toxic lesions induced by CsA and FK506 have been
described in both, proximal and distal tubules [16–18].
From immunohistochemical studies it is known that P-gp is
constitutively expressed in the brush border membrane of
human [3] and rat proximal tubule cells (RPTC) [34]. In the
present study, we also tested the effect of therapeutic
concentrations of CsA and FK506 on P-gp expression in a
Fig. 2. Time course of the effect of cyclosporine A (CsA) on the expression of P-gp in lysates from human arterial endothelial cells (HAEC). HAEC
were left untreated [0.1% (vol/vol) DMSO for 7 days] or exposed to 0.8 mM CsA for one to seven days. The immunoblot was probed with mAb C219
(5 mg/ml). Typical for three different preparations.
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Fig. 3. Immunocytochemical staining of P-gp
in the plasma membrane of human arterial
endothelial cells (HAEC) incubated without
and with cyclosporine A (CsA) or FK506 for
seven days. Cytospins of HAEC were fixed in
4% paraformaldehyde, incubated with MRK-16
mAb (1:100) and stained by immunoperoxidase
reaction. In (A), control HAEC had been
incubated with 0.1% (vol/vol) DMSO for seven
days. In (B and C), HAEC had been exposed to
0.8 mM CsA or 0.1 mM FK506 for seven days,
respectively. Typical for four different cytospin
preparations. Original magnification 3400.
Bar 5 15 mm.
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cell culture model of renal proximal tubules using immor-
talized cells derived from the S1 segment of kidney proxi-
mal tubule isolated from normotensive Wistar-Kyoto rats
[23]. P-gp was constitutively expressed in RPTC, as re-
flected by an immunoreactive band of about 170 kD (Fig.
5A, first lane). CsA treatment (0.1 to 1.6 mM) for seven days
increased P-gp expression in RPTC as a function of the
CsA concentration applied (Fig. 5A), similarly to that
observed in HAEC (Fig. 1), but the expression of the
a-subunit of Na1/K1-ATPase was not affected by CsA
treatment (Fig. 5B). Application of FK506 (0.1 to 0.2 mM)
for the same period of time did not significantly change the
expression of P-gp or Na1/K1-ATPase in RPTC cells (Fig.
5 A, B). However, higher concentrations of FK506 (0.6 to
1.2 mM) increased the expression of P-gp in RPTC by about
threefold (data not shown), in a similar manner to that
shown in HAEC (Fig. 1).
The transport function of P-gp was also investigated in
RPTC by measuring accumulation of the fluorescent dye
calcein. After the addition of 0.25 mM calcein-AM to
control RPTC, fluorescent calcein accumulated linearly
over time as a consequence of intracellular hydrolysis of
calcein-AM by cellular esterases (Fig. 6). The addition of
the P-gp inhibitor verapamil (100 mM; Fig. 6) to the cuvette
did not significantly affect the rate of calcein fluorescence
accumulation in the control- or FK506-treated cells, but
increased the rate in cells that had been incubated with 0.8
mM CsA for seven days (Fig. 6, CsA curve). The presence of
a verapamil-sensitive component of calcein accumulation
indicates a contribution of P-gp to calcein-AM extrusion.
This component had been induced by the CsA treatment.
DISCUSSION
The novel aspect of the present study is a comparison of
the effect of therapeutic concentrations of the immunosup-
pressive drugs CsA and FK506 on P-gp expression using
cultured cell lines of endothelial and proximal tubular
origin. Both cell lines were selected for these studies,
because they seemed to represent suitable in vitro models
of the renal structures in which immunosuppressive drug-
induced toxic lesions may occur [16–18], but also of the
human tissues that normally express P-gp [3, 4]. P-gp serves
as a major pump for cellular extrusion of CsA and FK506
[7] and thus its levels are expected to determine in part
cytosolic drug concentrations. Increased P-gp expression
Fig. 4. Fluorimetric time course of calcein
accumulation in suspensions of human arterial
endothelial cells (HAEC) incubated in the
absence and presence of verapamil. Five 3 105
cells/ml Tyrode solution were incubated in the
presence of 0.25 mM calcein-AM at 37°C. The
increase in fluorescence was monitored as the
dye was hydrolyzed intracellularly. The plot
shows calcein fluorescence (arbitrary units)
against time. The inhibitor of P-gp verapamil
(100 mM) was added where indicated. The
different curves represent experiments with
cells which had been exposed for seven days to
either 0.1% (vol/vol) DMSO (control), 0.8 mM
cyclosporine A (CsA), or 0.1 mM FK506
(FK506). Typical for three different
experiments.
Table 1. Effect of inhibitors of P-gp on calcein accumulation in human
arterial endothelial cells
Pretreatment of
cells
Accumulation ratio
DMSO
CsA
5 mM
Verapamil
100 mM
DMSO 1.63 6 0.12a 1.52 6 0.13 1.71 6 0.11
CsA 0.8 mM 3
7 days
1.52 6 0.13 3.31 6 0.10b 3.74 6 0.36b
FK506 0.1 mM
3 7 days
1.83 6 0.09 1.85 6 0.14 1.99 6 0.11
N 3 3 3
a The accumulation ratios shown (means 6 SD) were calculated by
dividing the rate of net calcein accumulation after addition of a drug (or
solvent DMSO) by the rate observed without drug. Slopes (rates) were
calculated from linear regression.
b P , 0.01 using unpaired Student’s t-test
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should therefore protect cells to some degree from the
noxious effects of the immunosuppressive drugs.
To evaluate modulation of P-gp levels by both drugs,
immortalized rat proximal tubule cells (RPTC) and human
arterial endothelial cells (HAEC) were incubated for pro-
longed periods (up to 7 days) with FK506 and CsA at
therapeutic concentrations. Therapeutic concentrations for
CsA and FK506 are well established. FK506 is in vivo at
least an order of magnitude more potent than CsA in terms
of immunosuppression [9–11]. Maximal plasma concentra-
tions of FK506 rarely exceed 0.1 mM [35], whereas for CsA
plasma peak values of 1 mM may be reached in renal
transplant recipients [36]. The results of this study indicate
that therapeutically comparable concentrations of the two
drugs differentially affect expression of P-gp, that is, of a
major transporter responsible for cellular extrusion of the
drugs. Treatment with 0.4 to 0.8 mM CsA for several days
increased P-gp expression and transport function two- to
threefold in endothelial as well as proximal tubule cells,
while treatment with 0.05 to 0.1 mM FK506 had no effect in
this respect (see Figs. 1 and 5 for expression, Figs. 4 and 6
and Table 1 for transport). At concentrations exceeding 0.5
mM FK506 P-gp expression was also increased in HAEC
and RPTC (Fig. 1B), but concentrations above 0.5 mM are
not in the therapeutic range of FK506.
In agreement with our results, Garcia del Moral et al [37]
have previously demonstrated overexpression of P-gp in
kidney biopsies of renal transplant recipients treated with
CsA, and also showed that chronic administration of CsA
to MDCK cells (2 mM for .60 days) increased P-gp
Fig. 5. Expression of P-gp (A) and Na1/K1-ATPase (B) in lysates from rat proximal tubule cells (RPTC) treated for seven days with different
concentrations of cyclosporine A (CsA) or FK506. (A) RPTC were exposed for seven days to either 0.1% (vol/vol) DMSO in controls (lane 1) and 0.1
to 1.6 mM CsA (upper immunoblot) or 0.01 to 0.2 mM FK506 (lower immunoblot) dissolved in 0.1% (vol/vol) DMSO. The immunoblot was probed with
mAb C219 (5 mg/ml). One out of five similar experiments is shown. (B) The immunoblot was probed with mAb Aba5 (0.5 mg/ml) directed against the
a-subunit of Na1/K1-ATPase. RPTC were pretreated for seven days with 0.1% (vol/vol) DMSO in controls (lane 1), 0.8 or 1.6 mM CsA, and 0.1 or 0.2
mM FK506. One out of three similar experiments is shown.
Hauser et al: Induction of P-gp by CsA and FK5061146
expression in vitro. Other studies have also shown an
increased expression of P-gp after exposure to suprathera-
peutic concentrations of CsA, both in cultured cells [19]
and in experimental animals [20]. Induction of P-gp by CsA
treatment also occurs in typical target cells of the immu-
nosuppressive effect of the drug, that is, in mononuclear
cells, which are of critical importance for the development
of rejection processes after organ transplantation. Kemnitz
et al described an increased incidence of rejection in heart
transplant recipients, who showed an induction of P-gp in
mononuclear cells of the peripheral blood after transplan-
tation under an immunosuppressive therapy with CsA,
azathioprine and dexamethasone [38]. Similar observations
have been made by Zanker et al, who correlated the
development of acute or chronic rejection with the percent-
age of P-gp expressing peripheral blood mononuclear cells
in kidney transplant recipients [39, 40]. Since FK506 did
not induce P-gp expression in HAEC and RPTC at thera-
peutic concentrations (Figs. 1, 2 and 5), this lack of
induction of P-gp may explain in part the efficacy of FK506
as an anti-rejection agent in CsA-resistant refractory allo-
graft rejection [13].
The mechanisms of T-cell immunosuppression by both
CsA and FK506 are relatively well understood [8]. In
contrast, the molecular basis of nephrotoxicity has not yet
been elucidated. The results of this study have implications
that need to be taken into account in the interpretation of
dose-response curves of both therapeutic and toxic side
effects of CsA and FK506. It is surprising that CsA and
FK506 display a comparable incidence of nephrotoxicity
[14, 15], despite a ;tenfold difference in the drug concen-
trations used for immunosuppression. From our results it is
tempting to speculate that the cytosolic concentration of
CsA or FK506 may be of similar magnitude, since CsA in
the concentration range of interest increases the level of a
transporter that lowers its cytosolic concentration. This
finding would suggest that efficacy for therapeutic as well as
toxic side effects of CsA will level off if P-gp is induced.
However, one should also be aware that peak CsA plasma
concentrations of 0.5 to 1 mM may also partially inhibit P-gp
mediated drug transport, as indicated by Bennett et al [41].
On the other hand, comparable cytosolic concentrations of
CsA and FK506 could have a major influence on the
“specific” immunosuppressive effect of both drugs in target
cells in vivo. The immunosuppressive activity of FK506
occurs at concentrations 10- to 100-fold lower (on a molar
basis) than that of CsA [9–11]. Therefore, cytosolic con-
centrations of FK506 in target cells would fall within the
immunosuppressive range, when compared to CsA, be-
cause of the higher immunosuppressive efficacy of the drug
and the lack of P-gp induction at the interesting concen-
tration range. However, a variable sensitivity of individual
patients to therapeutic and toxic side effects of CsA and
FK506 may also depend on baseline P-gp protein levels and
sensitivity for induction of additional P-gp by CsA.
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